Exenatide official document review · version 1
This page preserves this version's findings, scope and source pins. Open the current profile →
Inside the official reviews
Reviewed 2026-09-19 · Preserved version 1
The original trials tested add-on diabetes treatment
EMA’s original Byetta assessment evaluated exenatide added to existing glucose-lowering therapy in type 2 diabetes. HbA1c was the principal endpoint; weight change was a separate outcome. This is not the later extended-release or cardiovascular-outcomes evidence. EMA PDF pp. 25, 27 ↗
More findings, study links and document coverage
The insulin comparisons had an important limitation
Two active-comparator trials met the prespecified HbA1c noninferiority margin. EMA noted their open-label design and the possibility that insulin treatment had not been fully optimized, limiting claims that one treatment was better overall. EMA PDF pp. 25 ↗
Extension results require caution
EMA warned that more than 80% of extension participants withdrew or discontinued for administrative reasons after week 52. Favorable results among those remaining cannot alone establish durable benefit for everyone originally enrolled. EMA PDF pp. 25 ↗
Safety depends on accompanying treatment and follow-up
The review identifies nausea and vomiting as common problems and hypoglycemia particularly with sulfonylureas. Mean exposure was under a year, with limited experience in older people and impaired kidney function. EMA PDF pp. 26 ↗
Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.
Document coverage
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Byetta : EPAR - Scientific Discussion ↗
Selected sections reviewed · ema-36540 · Document/feed date: 2006-12-15
The undated initial scientific discussion names the product. Application identity comes from the separately pinned EMA medicine record, and the date is the documents-feed first-publication date, not an adoption date.
Verified: Byetta · EMEA/H/C/000698 · EMA first-publication date 2006-12-15. Product identity checked on PDF pp. 1.
The undated PDF does not print the application number. The application is reconciled separately against EMA medicine record EMEA/H/C/000698 ↗, retrieved 2026-09-15. Its first-publication date is not an assessment-adoption date.
Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 25, 26, 27 of 27. SHA-256:
406dfeecb0b57c3036d836ebf625e6aad6182143b50820c441500b79c3a2d1df.Feed-listed application (not a verified association): EMEA/H/C/000698.
Remaining work
- Review the separate Bydureon extended-release assessment and EXSCEL cardiovascular program.
- Reconcile later safety variations and full-text trial reports with their original study populations.